• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肉毒杆菌毒素治疗满意度:眼睑痉挛与颈部肌张力障碍的比较。

Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia.

作者信息

Leplow Bernd, Eggebrecht Anna, Pohl Johannes

机构信息

Department of Psychology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.

出版信息

Patient Prefer Adherence. 2017 Sep 14;11:1555-1563. doi: 10.2147/PPA.S141060. eCollection 2017.

DOI:10.2147/PPA.S141060
PMID:29066869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5605128/
Abstract

BACKGROUND

Differential effects of botulinum toxin (BoNT) treatment in cervical dystonia (CD) and blepharospasm (BSP) treatment satisfaction and emotional responses to a life with a disabling condition were investigated. Special interest was drawn to the course within a BoNT treatment cycle and the effects of subjective well-being vs perceived intensity of motor symptoms and quality of life.

METHODS

A questionnaire was distributed among 372 CD patients and 125 BSP patients, recruited from 13 BoNT centers throughout Germany. Items were related to dystonic symptoms, BoNT treatment responses and treatment satisfaction, quality of life, working situation, and emotional reactions to a life with dystonia.

RESULTS

CD patients and BSP patients were widely satisfied with BoNT treatment, but treatment satisfaction worsened significantly within the treatment cycle. Especially CD patients reported that both the dystonic symptoms and the effects of BoNT treatment were influenced by emotional factors. Despite good overall treatment effects, patients from both groups perceived marked persistence of motor symptoms, restrictions of everyday life functions, and reduced quality of life. Functional amelioration of motor symptoms and emotional well-being were only moderately correlated. About 22% of patients from both groups reported mental disorders or emotional disturbances prior to the onset of dystonia.

CONCLUSION

As numerous psychological factors determine perceived outcome, BoNT treatment should be further improved by patient's education strategies enhancing behavioral self-control. From the patient's perspective, individual intervals, which may avoid exacerbation between injection points, should be considered. Moreover, patients at risk, with reduced adherence and poor BoNT outcome, should be identified and addressed within psychoeducation.

摘要

背景

研究了肉毒杆菌毒素(BoNT)治疗对颈部肌张力障碍(CD)和眼睑痉挛(BSP)治疗满意度以及对残疾生活的情绪反应的不同影响。特别关注了BoNT治疗周期内的过程以及主观幸福感与运动症状感知强度和生活质量的影响。

方法

向从德国各地13个BoNT治疗中心招募的372例CD患者和125例BSP患者发放问卷。问卷项目涉及肌张力障碍症状、BoNT治疗反应和治疗满意度、生活质量、工作状况以及对肌张力障碍生活的情绪反应。

结果

CD患者和BSP患者对BoNT治疗普遍满意,但治疗满意度在治疗周期内显著恶化。尤其是CD患者报告说,肌张力障碍症状和BoNT治疗效果均受情绪因素影响。尽管总体治疗效果良好,但两组患者均感觉到运动症状持续存在、日常生活功能受限以及生活质量下降。运动症状的功能改善与情绪幸福感仅呈中度相关。两组中约22%的患者在肌张力障碍发作前报告有精神障碍或情绪障碍。

结论

由于众多心理因素决定了感知结果,应通过加强行为自我控制的患者教育策略进一步改善BoNT治疗。从患者角度来看,应考虑可能避免注射点之间症状加重的个体化间隔时间。此外,应在心理教育中识别并处理有风险、依从性降低且BoNT治疗效果不佳的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/45ad45cde1fd/ppa-11-1555Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/cc94c813a7a0/ppa-11-1555Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/77e0038cbe7b/ppa-11-1555Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/61e6b348cdaa/ppa-11-1555Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/196d5bdc283e/ppa-11-1555Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/45ad45cde1fd/ppa-11-1555Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/cc94c813a7a0/ppa-11-1555Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/77e0038cbe7b/ppa-11-1555Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/61e6b348cdaa/ppa-11-1555Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/196d5bdc283e/ppa-11-1555Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6906/5605128/45ad45cde1fd/ppa-11-1555Fig5.jpg

相似文献

1
Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia.肉毒杆菌毒素治疗满意度:眼睑痉挛与颈部肌张力障碍的比较。
Patient Prefer Adherence. 2017 Sep 14;11:1555-1563. doi: 10.2147/PPA.S141060. eCollection 2017.
2
Cervical dystonia: factors deteriorating patient satisfaction of long-term treatment with botulinum toxin.颈肌张力障碍:影响肉毒毒素长期治疗患者满意度的因素。
Neurol Res. 2020 Nov;42(11):987-991. doi: 10.1080/01616412.2020.1796430. Epub 2020 Jul 22.
3
Long-term adherence and response to botulinum toxin in different indications.不同适应证下肉毒毒素的长期依从性和应答反应。
Ann Clin Transl Neurol. 2021 Jan;8(1):15-28. doi: 10.1002/acn3.51225. Epub 2020 Dec 1.
4
A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.一种治疗局限性肌张力障碍的新方法:无复合蛋白的肉毒神经毒素 A 型(Xeomin®)。
Neuropsychiatr Dis Treat. 2012;8:13-25. doi: 10.2147/NDT.S16085. Epub 2011 Dec 23.
5
Botulinum toxin and blink rate in patients with blepharospasm and increased blinking.肉毒杆菌毒素与眨眼率在眼睑痉挛和眨眼增多的患者中的应用。
J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):336-40. doi: 10.1136/jnnp-2014-307821. Epub 2014 Jun 24.
6
Effect of Botulinum Toxin on Non-Motor Symptoms in Cervical Dystonia.肉毒毒素对颈肌张力障碍非运动症状的影响。
Toxins (Basel). 2021 Sep 12;13(9):647. doi: 10.3390/toxins13090647.
7
Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia.长期接受治疗的局限性肌张力障碍患者,A型肉毒杆菌神经毒素可改善其健康相关生活质量。
J Neurol Neurosurg Psychiatry. 2001 Aug;71(2):193-9. doi: 10.1136/jnnp.71.2.193.
8
Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment.肉毒杆菌毒素治疗颈部肌张力障碍的疼痛缓解
Toxins (Basel). 2015 Jun 23;7(6):2321-35. doi: 10.3390/toxins7062321.
9
Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study.长期肉毒毒素治疗痉挛性斜颈患者的生活质量:一项横断面研究的结果。
Parkinsonism Relat Disord. 2018 Dec;57:63-67. doi: 10.1016/j.parkreldis.2018.07.019. Epub 2018 Jul 31.
10
The impact of blepharospasm and cervical dystonia on health-related quality of life and depression.眼睑痉挛和颈部肌张力障碍对健康相关生活质量及抑郁的影响。
J Neurol. 2002 Jul;249(7):842-6. doi: 10.1007/s00415-002-0733-1.

引用本文的文献

1
Exploration of potential immune mechanisms in cervical dystonia.颈部肌张力障碍潜在免疫机制的探索
Parkinsonism Relat Disord. 2024 May;122:106036. doi: 10.1016/j.parkreldis.2024.106036. Epub 2024 Feb 17.
2
An Exploratory, Randomized, Double-Blind Clinical Trial of Dipraglurant for Blepharospasm.眼睑痉挛的探索性、随机、双盲临床试验中的 Dipraglurant
Mov Disord. 2024 Apr;39(4):738-745. doi: 10.1002/mds.29734. Epub 2024 Feb 3.
3
Individual Response to Botulinum Toxin Therapy in Movement Disorders: A Time Series Analysis Approach.

本文引用的文献

1
Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia.追求更多美好时光:患者对肉毒杆菌毒素治疗颈部肌张力障碍的看法。
Patient Prefer Adherence. 2016 Aug 22;10:1601-8. doi: 10.2147/PPA.S106560. eCollection 2016.
2
Determinants of disability in cervical dystonia.颈部肌张力障碍致残的决定因素。
Parkinsonism Relat Disord. 2016 Nov;32:48-53. doi: 10.1016/j.parkreldis.2016.08.014. Epub 2016 Aug 15.
3
Cervical dystonia and quality of life.颈部肌张力障碍与生活质量。
个体对运动障碍肉毒毒素治疗的反应:时间序列分析方法。
Toxins (Basel). 2022 Jul 24;14(8):508. doi: 10.3390/toxins14080508.
4
Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle.在肉毒毒素治疗周期中,评估颈肌张力障碍和半面痉挛的主观症状强度与客观症状强度。
Brain Behav. 2021 Mar;11(3):e02023. doi: 10.1002/brb3.2023. Epub 2021 Jan 5.
5
Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.采用 ABO 和 ONABOTULINUMTOXINA 治疗颈肌张力障碍:日常临床实践中的长期安全性和疗效。
J Neurol. 2019 Aug;266(8):1879-1886. doi: 10.1007/s00415-019-09349-2. Epub 2019 May 2.
Acta Neurol Belg. 2016 Dec;116(4):589-592. doi: 10.1007/s13760-016-0634-1. Epub 2016 May 2.
4
Is it time for flexibility in botulinum inter-injection intervals?是时候灵活调整肉毒杆菌素注射间隔了吗?
Toxicon. 2015 Dec 1;107(Pt A):72-6. doi: 10.1016/j.toxicon.2015.09.037. Epub 2015 Oct 9.
5
Non-motor symptoms in patients with adult-onset focal dystonia: Sensory and psychiatric disturbances.成人起病型局灶性肌张力障碍患者的非运动症状:感觉和精神障碍。
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S111-4. doi: 10.1016/j.parkreldis.2015.09.001. Epub 2015 Sep 3.
6
Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A.颈部肌张力障碍治疗中的患者考量:聚焦A型肉毒毒素
Patient Prefer Adherence. 2015 Jun 2;9:725-31. doi: 10.2147/PPA.S75459. eCollection 2015.
7
Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.肉毒杆菌毒素治疗相关的慢性每日头痛管理实用指南:共识声明
J Neurol. 2015 Oct;262(10):2201-13. doi: 10.1007/s00415-015-7703-x. Epub 2015 Apr 1.
8
Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study.影响颈部肌张力障碍患者健康相关生活质量的因素及阿扑肉毒毒素A(Dysport)治疗的影响:一项随机、双盲、安慰剂对照研究的结果
BMJ Open. 2014 Oct 16;4(10):e005150. doi: 10.1136/bmjopen-2014-005150.
9
IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.按需注射用于治疗眼睑痉挛或颈部肌张力障碍的因可 BotulinumtoxinA(Xeomin®)耐受性良好。
J Neurol Sci. 2014 Nov 15;346(1-2):116-20. doi: 10.1016/j.jns.2014.08.004. Epub 2014 Aug 10.
10
Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects.肉毒杆菌毒素治疗颈部肌张力障碍:治疗效果的持续时间。
J Neural Transm (Vienna). 2015 Feb;122(2):297-300. doi: 10.1007/s00702-014-1253-8. Epub 2014 Jul 23.